Valneva
Logotype for Valneva SE

Valneva (VLA) investor relations material

Valneva Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Valneva SE
Jefferies Global Healthcare Conference summary16 Nov, 2026

Lyme disease program and regulatory path

  • Phase III efficacy was 73.2%; the primary analysis narrowly missed its prespecified confidence-interval threshold, while a second prespecified analysis including one additional placebo case cleared it. The safety profile was described as excellent.

  • EMA review clearance was completed and the application submitted and accepted; a Health Canada submission followed. Pfizer is leading ongoing FDA discussions on the BLA data package and post-marketing requirements.

  • The proposed U.S. licensure package combines the totality of clinical evidence, including a correlate-of-risk analysis linking immunogenicity to Lyme cases, case reviews over time and booster data, plus risk-benefit and health-economic analyses.

  • BLA timing shifted as FDA discussions continue on evidence and post-marketing requirements, which Lingelbach said FDA expects resolved before submission. He hoped for submission before Christmas 2026; delay could risk losing a commercial year due to Lyme seasonality.

  • A VRBPAC meeting is assumed; Lingelbach expressed confidence in a positive outcome, with risk-benefit, health-economic benefit and the totality of evidence expected to be central. No additional FDA study was anticipated.

Lyme commercial outlook

  • European licensure remains expected in fall 2027, with a possible launch in key countries that fall; Pfizer’s tick-disease and TBE commercial capabilities were cited as potential support for a launch.

  • In Europe, an initial launch phase may precede final vaccine recommendations, which can take time; reimbursement in some EU countries was discussed as a 9–12-month process.

  • Pfizer has publicly projected annual sales north of $1B; market analyses cited a $1B–$3B opportunity. High-risk populations were stated as more than 200M in Europe and 80M–90M in the U.S.

Shigella and pipeline priorities

  • The adult controlled human infection model met its primary endpoint, and the infant study showed significant anti-LPS IgG increases across four serotypes; the challenge model worked and immunogenicity correlated with efficacy.

  • Shigella responses were inconsistent across participants, indicating a need to optimize dose and schedule. Studies are being planned but will not start until there is greater Lyme clarity and funding certainty; progression in adults and children could resume thereafter.

  • Shigella could advance to its next development stage in late 2027. Clinical entry for EBV has been slowed; the EBV asset was described as differentiated, with potential to explore enteric combination vaccines.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Valneva earnings date

Logotype for Valneva SE
Q3 202624 Nov, 2026
Valneva
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Valneva earnings date

Logotype for Valneva SE
Q3 202624 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Valneva SE is a specialty vaccine company focused on developing and commercializing vaccines for infectious diseases. It targets diseases with significant unmet medical needs through proprietary and partnered programs. The company is headquartered in Saint-Herblain, France, and its shares are listed on the Euronext Paris.